Friday, January 30, 2026

Kim Jong Un Celebrates 80th Anniversary of Youth Alliance: What It Means for North Korea’s Future?

Kim Jong Un celebrated the 80th anniversary of the Socialist Patriotic Youth League, emphasizing youth's vital role in North Korea's future.

DeepL Partners with Saltlux Innovation to Expand Multilingual Communication Services

DeepL partners with Saltlux Innovation to enhance multilingual services for 15,000 corporate clients, offering advanced AI translation tools.

Why Kim Jong Un’s Public Appearances Have Plummeted: A Deep Dive into North Korea’s Leadership Dynamics

Kim Jong Un has reduced public appearances, raising security concerns after U.S. actions in Venezuela and a drone incident with South Korea.

Tag: trial

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

JW Pharmaceutical Secures U.S. Patent for Hair Loss Drug Candidate JW0061

JW Pharmaceutical secures a U.S. patent for hair loss treatment JW0061, targeting GFRA1 receptor, ensuring market exclusivity until 2039.

Amid Rising Drug Resistance, Korea Begins DOMINO Trial to Reassess First-Line Treatment for Pediatric Mycoplasma

The DOMINO trial will assess treatments for pediatric Mycoplasma pneumonia, addressing rising macrolide resistance in Korea.

Unlocking Convenience: Rolvedon’s Same-Day Chemotherapy Solution for Neutropenia Revealed

Hanmi Pharmaceutical's Rolvedon shows potential for same-day chemotherapy administration, improving patient convenience and market competitiveness.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

SK Biofarm, FDA Approved Radioactive Method: Will it be a Revolutionary Cancer Cure with SLK 33501?

SK Biopharmaceuticals gains FDA approval for Phase 1 trials of radiopharmaceuticals SKL35501 and SKL35502, advancing cancer treatment.

Cancer Gone for 3 Years? This New Drug Is Making It Happen

AbbVie's Epkinly shows 96% long-term complete remission in R/R large B-cell lymphoma patients, highlighting its effectiveness as a therapy.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.